Summary Most cancer radiation therapy accelerators purchased today have gantry-mounted imagers, typically used to image the patient prior to treatment. We imaged prostate cancer patients during their treatment. Combining images with marker segmentation software and a 2- to 3-dimensional reconstruction method, we were able to measure prostate motion during the treatment to within submillimeter accuracy. Because intrafraction prostate monitoring method uses widely available clinical equipment, intratreatment prostate motion monitoring could become routine. Purpose Most linear accelerators purchased today are equipped with a gantry-mounted kilovoltage X-ray imager which is typically used for patient imaging prior to therapy. A novel application of the X-ray system is kilovoltage intrafraction monitoring (KIM), in which the 3-dimensional (3D) tumor position is determined during treatment. In this paper, we report on the first use of KIM in a prospective clinical study of prostate cancer patients undergoing intensity modulated arc therapy (IMAT). Methods and Materials Ten prostate cancer patients with implanted fiducial markers undergoing conventionally fractionated IMAT (RapidArc) were enrolled in an ethics-approved study of KIM. KIM involves acquiring kV images as the gantry rotates around the patient during treatment. Post-treatment, markers in these images were segmented to obtain 2D positions. From the 2D positions, a maximum likelihood estimation of a probability density function was used to obtain 3D prostate trajectories. The trajectories were analyzed to determine the motion type and the percentage of time the prostate was displaced ≥3, 5, 7, and 10 mm. Independent verification of KIM positional accuracy was performed using kV/MV triangulation. Results KIM was performed for 268 fractions. Various prostate trajectories were observed (ie, continuous target drift, transient excursion, stable target position, persistent excursion, high-frequency excursions, and erratic behavior). For all patients, 3D displacements of ≥3, 5, 7, and 10 mm were observed 5.6%, 2.2%, 0.7% and 0.4% of the time, respectively. The average systematic accuracy of KIM was measured at 0.46 mm. Conclusions KIM for prostate IMAT was successfully implemented clinically for the first time. Key advantages of this method are (1) submillimeter accuracy, (2) widespread applicability, and (3) a low barrier to clinical implementation. A disadvantage is that KIM delivers additional imaging dose to the patient.

A method for accurate dose reconstruction for moving targets with dynamic treatments was developed and experimentally validated in a variety of delivery scenarios. The method is suitable for integration into TPSs, e.g., for reconstruction of the dose delivered to moving tumors or calculation of target doses delivered with DMLC tracking.

Purpose Intensity modulated arc therapy (IMAT) enables efficient and highly conformal dose delivery. However, intrafraction motion may compromise the delivered target dose distribution. Dynamic MLC (DMLC) tracking can potentially mitigate the impact of target motion on the dose. The purpose of this study was to use a single kV imager for DMLC tracking during IMAT and to investigate the ability of this tracking to maintain the dose distribution. Methods A motion phantom carrying a 2D ion chamber array and build-up material with an embedded gold marker reproduced eight representative tumor trajectories(four lung tumors,four prostate). For each trajectory, a low and high intensity modulated IMAT plan were delivered with and without DMLC tracking. The 3D real-time target position signal for tracking was provided by fluoroscopic kV images acquired immediately before and during treatment. For each image, the 3D position of the embedded marker was estimated from the imaged 2D position by a probability based method. The MLC leaves were continuously refitted to the estimated 3D position. For lung, prediction was used to compensate for the tracking latency. The delivered 2D dose distributions were measured with the ion chamber array and compared with a reference dose distribution delivered without target motion using a 3%/3mm γ-test. Results For lung tumor motion, tracking reduced the mean γ-failure rate from 38% to 0.7% for low modulation IMAT plans and from 44% to 2.8% for high modulation plans. For prostate, the γ-failure rate reduction was from 19% to 0% (low modulation) and from 20% to 2.7% (high modulation). The dominating contributor to the residual γ-failures during tracking was target localization errors for most lung cases and leaf fitting for most prostate cases. Conclusion Image-based tracking for IMAT was demonstrated for the first time. The tracking greatly improved the dose distributions to moving targets.

Compared to free breathing treatments, the primary benefit of the DIBH technique was the separation of the heart from the target rather than more accurate targeting. Despite a small gating window, occasional large errors in the chest wall position were observed for some patients, illustrating limitations of the external marker block as surrogate in a broad patient population.

For the first time, KIM has been used for real-time image guidance during cancer radiotherapy. The measured accuracy and precision were both submillimeter for the first treatment fraction. This clinical translational research milestone paves the way for the broad implementation of real-time image guidance to facilitate the detection and correction of geometric and dosimetric errors, and resultant improved clinical outcomes, in cancer radiotherapy.